Sensitive endpoints for established disease where standard scales plateau
Patients with established Alzheimer's disease present a different measurement challenge. Standard cognitive scales show progressive decline but lose granularity as scores approach their floor. For trials testing interventions aimed at slowing decline or achieving stabilization, consolidation-based endpoints may detect meaningful change that composites average away.
The Floor Effect Problem
In mild to moderate AD, many ADAS-Cog items approach floor performance. A patient scoring near zero on a subtest cannot decline further on that measure, compressing the scale's dynamic range. CDR-SB captures functional decline but reflects caregiver perception and daily activity changes that lag behind underlying cognitive change. Sponsors need endpoints that remain sensitive across the full severity range studied.
Why Consolidation Matters for Established AD
Even in established Alzheimer's disease, consolidation-based measurement provides clinical signal. Patients retain some encoding capacity but show severe overnight forgetting. A therapy that preserves or partially restores consolidation function would produce detectable change on FaceWise even when broad cognitive composites show only noise. Adaptive encoding in FaceWise ensures each participant reaches a learning criterion before the delay period, isolating the consolidation signal regardless of baseline severity.
Published Evidence
Research supporting consolidation-based endpoints for mild to moderate alzheimer's disease assessment.
Floor Effects in ADAS-Cog
Psychometric analyses demonstrate that multiple ADAS-Cog subtests show floor effects in moderate AD, reducing effective test-retest reliability and sensitivity to treatment-related change in the population most in need of effective therapies.
Published ADAS-Cog psychometric literature
Consolidation Deficit Progression
Overnight forgetting rates increase from aMCI through mild and moderate AD in a dose-response pattern consistent with progressive hippocampal and sleep architecture degradation. This provides a continuous measurement axis without the categorical thresholds that limit ordinal scales.
Walsh CM, et al. Neurobiology of Aging, 2014
Encoding Adaptation Preserves Signal
Adaptive titration to a learning criterion before the delay period ensures that the overnight forgetting measure reflects consolidation capacity, not encoding failure. This is critical for maintaining endpoint sensitivity across the mild to moderate severity range.
FaceWise assessment design rationale
Trial Applications
Clinical trial contexts where FaceWise consolidation endpoints add value for mild to moderate alzheimer's disease programs.
Ready to discuss mild to moderate alzheimer's disease endpoints?
Schedule a consultation to explore how FaceWise consolidation endpoints can strengthen your mild to moderate alzheimer's disease clinical program.